CERS - Health Canada approves extended shelf life for Cerus' blood system treated platelets

• Cerus ( NASDAQ: CERS ) on Tuesday said Canada's drug regulator had approved extending the storage of platelets treated with the company's blood system from five days to seven days from the time of collection.
• CERS' INTERCEPT Blood System is used to reduce pathogens in platelets and plasma.
• The extended shelf life approval from Health Canada means that the country joins other territories where INTERCEPT platelets are approved for seven-day storage.
• CERS had entered into a contract in May last year with charitable organization Canadian Blood Services to implement their pathogen reduced platelets in the regions they serve.
• With the approval for the extended shelf life, Canadian Blood Services is now planning for a broader implementation across its markets, CERS said in a statement .
• CERS stock closed -0.5% at $3.66 on Monday.

For further details see: